This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or recommend these compounds.
Old habit: I write down the expected answer before I calculate it.
The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and the distinction matters, but it also means treatment plans based on these compounds are being built on theoretical grounds, not empirical ones.
I would put this at better than even and not much better.
For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or recommend these compounds.
I have deliberately not rounded that, because the rounding is where the argument starts.
Post #34 and I disagree about the size of the effect, not about the direction.
Where I would push back on the absence of controlled human data consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
Narrowing post #36, because the general version has more than one answer.
The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.
Everything in post #38 holds. The case it does not cover is the one I have.
An update on my earlier absence of controlled human data post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
On post #39 — agreed on the reasoning, with one qualification.
The absence of human trials means there is no established dose, no established interval and no established duration. Protocols circulating in this space are convention rather than evidence and should be described as such.
That is a description of practice, not a recommendation of it.
Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
Offering a way to settle absence of controlled human data rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.
Post #43 is the version of this I will quote in future. One addition.
Mechanistic accounts in this area run well ahead of the outcome data. Angiogenesis and cell migration effects in a dish are real observations and are a long way from a clinical result.
It is one reading of the data and not the only reasonable one.
BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.
The interesting part of this is the exception, and I do not understand the exception.
I read post #48 twice before replying, because I had assumed the opposite.
Something worth flagging about absence of controlled human data: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a coincidence.
Post #48 answers the question as asked. The question underneath it is different.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
I have left out the parts I could not verify.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
The general case is well covered; this is the awkward specific one.
Post #48 put the caveat in the right place and I want to underline it.
The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
What I would want before treating absence of controlled human data as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing.
Reading back through the absence of controlled human data threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
No disagreement from me. Posting only so the question does not look ignored.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Why the absence of controlled human data on BPC-157 matters more than people admit
Why the absence of controlled human data on BPC-157 matters more than people admit — that is the question, and I have not found it answered plainly anywhere I have looked. I would like to know what people…
|
+60 | 66 | 16k | 1d |
|
Why plausible mechanism is not evidence of effect
Asking directly, because I could not find a straight answer: Why plausible mechanism is not evidence of effect What changes if the standard account of plausible mechanism is wrong? I ask because I have been…
|
+14 | 18 | 57k | 13mo |
|
[2026 update] Publication patterns in the BPC-157 literature, examined
Publication patterns in the BPC-157 literature, examined Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a question about a…
|
+15 | 19 | 11k | 4mo |
|
Why plausible mechanism is not evidence of effect — one year on
The question in the title: Why plausible mechanism is not evidence of effect — one year on I will give what I have already checked below so nobody repeats it. What changes if the standard account of plausible…
|
+3 | 7 | 3.6k | 13mo |
|
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold?
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. The question about Analytical…
|
+28 | 33 | 1.6k | 1mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
The "under review" status pill and when a moderator applies it — a second dataset
The "under review" status pill and when a moderator applies it — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. A question about how this site should cite…
|
+50 | 54 | 1.4k | 11mo |
|
Triple agonism: additive, synergistic, or neither?
The question in the title: Triple agonism: additive, synergistic, or neither? I will give what I have already checked below so nobody repeats it. Asking about triple agonism on behalf of the question I keep…
|
+71 | 80 | 38k | 11mo |
|
Ipamorelin selectivity claims and where they came from — a second dataset
Posting this under the heading it deserves: Ipamorelin selectivity claims and where they came from — a second dataset Everything below is what sits behind that. Posting a small dataset on Ipamorelin…
|
2 | 27k | 14mo | |
|
Publication patterns in the BPC-157 literature, examined
Posting this under the heading it deserves: Publication patterns in the BPC-157 literature, examined Everything below is what sits behind that. Putting the numbers in the first post, because a question about…
|
+40 | 45 | 3.4k | 21h |
|
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset
On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. The question about BPC-157 that I actually want…
|
+77 | 84 | 54k | 11mo |